Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Wednesday, May 18, 2022

Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial

alexandrossfakianakis shared this article with you from Inoreader

13063.jpg

A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and provided therapeutic benefit lasting 6 months in pat...
View on Web

No comments:

Post a Comment